What is a preferred regimen for metastatic leiomyosarcoma after failure of doxorubicin/olaratumab and gemcitabine/docetaxel?
No actionable mutations were identified on next generation genomic sequencing.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · The Royal Marsden
Answered on
What is a preferred regimen for metastatic leiomyosarcoma after failure of doxorubicin/olaratumab and gemcitabine/docetaxel?
I would consider treatment with either trabectedin or pazopanib.
Join for free or sign in to see the full answer